Andelyn Biosciences

Columbus, OH
AAV
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-02
61.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (9) ○ EMA GMP ○ MHRA GMP

Quick Facts: Andelyn Biosciences

Signal Score
61.5/100 (as of 2026-04-02)
Quality Compliance
Assessment pending
Headquarters
Columbus, OH
Modalities
AAV
Active Programs
No ClinicalTrials.gov matches confirmed — 1 partnership announcement in press
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 1 partnership announcement found in press monitoring.
Programs no verified data
Sponsorsno verified data
ModalitiesAAV
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 68.0
Parent company: Nationwide Children's Hospital spinout
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Nationwide Children's Hospital spinout
Financial assessment: 68.0/100
Capacity 55.0
1 manufacturing site: Columbus, OH
Modalities: AAV
Capacity assessment: 55.0/100
Sites: Columbus, OH
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
StatusAvailable
1 manufacturing site: Columbus, OH
Modalities: AAV
Capacity assessment: 55.0/100
Sites: Columbus, OH
Recent Press9 articles
1 manufacturing site: Columbus, OH
Modalities: AAV
Capacity assessment: 55.0/100

Recent News 9 articles

general 2026-03-22
Andelyn and Amplo link on AAV gene therapy for NMJ conditions - MSN
Andelyn and Amplo link on AAV gene therapy for NMJ conditions  MSN
general 2026-03-22
Andelyn and Amplo link on AAV gene therapy for NMJ conditions - MSN
Andelyn and Amplo link on AAV gene therapy for NMJ conditions  msn.com
general 2026-03-20
Andelyn Biosciences Debuts Foundation to Back Rare Disease Family Nonprofits - Precision Medicine Online
Andelyn Biosciences Debuts Foundation to Back Rare Disease Family Nonprofits  Precision Medicine Online
general 2026-03-10
Andelyn Biosciences Establishes The Andelyn Foundation to Support Families Living with Rare and Ultra-Rare Diseases - PR Newswire
Andelyn Biosciences Establishes The Andelyn Foundation to Support Families Living with Rare and Ultra-Rare Diseases  prnewswire.com
partnership 2026-02-19
Andelyn Bio and Drake Rayden collaborate on AAVs for rare pediatric disease - BioProcess International
Andelyn Bio and Drake Rayden collaborate on AAVs for rare pediatric disease  BioProcess International
general 2026-02-18
Andelyn Biosciences Selected to Manufacture AAV Gene Therapy for Rare NKH Disorder - Contract Pharma
Andelyn Biosciences Selected to Manufacture AAV Gene Therapy for Rare NKH Disorder  Contract Pharma
general 2026-02-18
Andelyn Biosciences Selected To Manufacture Clinical Grade AAV Gene Therapy For Rare NKH Treatment - BioSpectrum Asia
Andelyn Biosciences Selected To Manufacture Clinical Grade AAV Gene Therapy For Rare NKH Treatment  BioSpectrum Asia
general 2026-02-17
Andelyn Biosciences to Apply the AAV Curator® Platform to Manufacture Clinical Grade AAV for Drake Rayden Foundation for the Treatment of Nonketotic Hyperglycinemia - PR Newswire
Andelyn Biosciences to Apply the AAV Curator® Platform to Manufacture Clinical Grade AAV for Drake Rayden Foundation for the Treatment of Nonketotic Hyperglycinemia  PR Newswire
general 2026-02-17
Andelyn Biosciences to Apply the AAV Curator® Platform to Manufacture Clinical Grade AAV for Drake Rayden Foundation for the Treatment of Nonketotic Hyperglycinemia - Morningstar
Andelyn Biosciences to Apply the AAV Curator® Platform to Manufacture Clinical Grade AAV for Drake Rayden Foundation for the Treatment of Nonketotic Hyperglycinemia  Morningstar
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs →

Similar CDMOs

Cincinnati Children's Vector Production Facility
Cincinnati, OH
Signal Score: 75.2
AAV, Lentiviral
Forge Biologics
Columbus, OH
Signal Score: 62.7
AAV
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Pharmaron Biologics
San Diego, CA · Shaoxing, CN
Signal Score: 85.6
AAV, Lentiviral, Plasmid